Skip to main content
Medical information Clinical review pending

Diagnostic Testing

Immunohistochemistry Isocitrate Dehydrogenase IDH1 Test

The Immunohistochemistry Isocitrate Dehydrogenase IDH1 Test helps identify specific genetic mutations in tumor tissue, aiding in the diagnosis and treatment planning for certain cancers like gliomas and AML.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample (e.g., biopsy) in 10% Formal-saline or Formalin fixed paraffin embedded block.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the laboratory receives the tumor tissue sample along with a copy of the Histopathology report, biopsy site information, and relevant clinical history.
Test priceKSh 7,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry Isocitrate Dehydrogenase IDH1 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of specific cancer types
  • ✓Prognosis assessment in certain cancers
  • ✓Guiding treatment decisions
  • ✓Identifying potential therapeutic targets
  • ✓Characterizing tumor genetics
02

In plain language

What this test helps you understand

Identifies IDH1 mutations in tumor tissue, aiding in cancer diagnosis, prognosis, and treatment planning, particularly for gliomas and AML.
The Immunohistochemistry Isocitrate Dehydrogenase IDH1 Test is a specialized diagnostic tool used primarily in oncology. It helps identify mutations in the IDH1 gene, which are found in various types of cancer, including certain brain tumors (gliomas) and blood cancers (acute myeloid leukemia - AML). Detecting these mutations provides valuable information for doctors to make informed decisions about treatment and patient care.

This test specifically looks for the presence of IDH1 mutations within a sample of tumor tissue. These mutations can influence how a cancer behaves, its likely progression, and how it might respond to different therapies. Understanding these genetic markers is increasingly important for personalized cancer treatment.

This test is typically recommended for patients diagnosed with or suspected of having specific types of tumors, such as gliomas or AML. It can also be considered in cases where understanding the genetic makeup of a tumor is crucial for guiding treatment decisions.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the laboratory receives the tumor tissue sample along with a copy of the Histopathology report, biopsy site information, and relevant clinical history.
SampleTumor tissue sample (e.g., biopsy) in 10% Formal-saline or Formalin fixed paraffin embedded block.
MethodologyImmunohistochemistry (IHC) technique used to detect IDH1 protein expression or mutations in tissue sections.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects IDH1 mutations in the provided tissue sample. Results are specific to the sample tested and may not reflect the entire tumor or potential future changes. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The IDH1 gene provides instructions for making an enzyme involved in cellular metabolism. Mutations in this gene can contribute to cancer development.
Identifying IDH1 mutations helps doctors understand the specific type of cancer, predict its behavior, and choose the most effective treatment strategies.
A sample of the tumor tissue, typically obtained through a biopsy, is required. The sample should be properly preserved in formalin.
Confirm with the laboratory before booking.
A positive result indicates the presence of IDH1 mutations. Your doctor will interpret these results in the context of your overall health and diagnosis.
Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp